Navigation Links
Pegloticase BLA Filing Accepted for Priority Review by FDA
Date:12/29/2008

ANGUAGE

All statements other than statements of historical facts included in this press release are forward-looking statements that are subject to certain risks, trends and uncertainties that could cause actual results and achievements to differ materially from those expressed in such statements. These risks, trends and uncertainties are in some instances beyond our control. Words such as "anticipate," "believe," "estimate," "expect," "intend," "plan," "will" and other similar expressions help identify forward-looking statements, although not all forward-looking statements contain these identifying words. In particular, any statements regarding our BLA filing with the FDA, a potential Advisory Committee, approval of the BLA, preparation for commercialization of pegloticase, the efficacy and safety of pegloticase and the market for pegloticase, are forward-looking statements. These forward-looking statements involve substantial risks and uncertainties and are based on our current assessment of the Phase 3 clinical data and on current expectations, assumptions, estimates and projections about our business and the biopharmaceutical and specialty pharmaceutical industries in which we operate. Important factors that may affect our ability to achieve the matters addressed in these forward-looking statements include, but are not limited to, the delay or failure in completing development of pegloticase and developing other product candidates; our stock price and market conditions; varying interpretations of our clinical and CMC data by the FDA; delay achieving or failure to achieve FDA approval of pegloticase; inability to manufacture commercial quantities of our products; inability to gain market acceptance sufficient to justify development and commercialization costs if our products are approved for marketing; our continuing to incur substantial net losses for the foreseeable future; difficulties in obtaining financing; potential development of alternative or
'/>"/>

SOURCE Savient Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine news :

1. Savients Board of Directors Forms a Board Committee to Oversee the Regulatory and Pre-Launch Activities for Pegloticase
2. Barrs BLA for Adenovirus Type 4 and 7 Live Oral Vaccines Accepted for Filing by FDA
3. Accuray Receives Nasdaq Notification Related to the Late Filing of Form 10-Q
4. Watson Announces the NDA for a 6-Month Formulation of TRELSTAR(R) Accepted for Filing by FDA for the Treatment of Advanced Prostate Cancer
5. Debiopharm Announces U.S. NDA Filing of Trelstar(R) 6-Month Formulation for Locally Advanced or Metastatic Prostate Cancer
6. KV Pharmaceutical Company Files Form Reporting Delay in Filing Second Quarter Form 10-Q
7. Corporate Parent Hospital Partners of America Files Voluntary Chapter 11 Petition; Filings do not Include any Hospital Facilities
8. VaxGen Provides Financial Update Following the Filing of Its 10-Q for Second Quarter With SEC; Results Include $8.5 Million Charge in Respect of Manufacturing Plant Asset Impairment
9. Wound Management Technologies, Inc. Announces Filing of a 510K
10. Digestive Care, Inc. Announces the Filing of the First Module of NDA Submission for PANCRECARB(R) (pancrelipase)
11. Statement Regarding the Filing of Signatures to Put the Human Embryo Stem Cell Issue on the November Statewide Ballot
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/29/2015)... ... July 29, 2015 , ... It is unique for ... is a tremendous model of care. One that is very hands on and resident ... director of Monarch Landing. “She’s bringing great passion and energy, as well as a ...
(Date:7/29/2015)... Palatine, IL (PRWEB) , ... July 29, 2015 , ... ... the ever-expanding population of children with autism, Little City took a proactive stance and ... and occupied. The Coleman Foundation grant provides valuable support to building the third home. ...
(Date:7/29/2015)... ... July 29, 2015 , ... Zofran lawsuits around the nation ... Litigation (JPML), according to court documents.* Attorneys handling Zofran lawsuits provide ... Defects Lawsuit Center. , GlaxoSmithKline, the global pharmaceutical conglomerate and defendant in national ...
(Date:7/29/2015)... ... , ... " mybody ” was featured on NewsWatch as part of its ... an impact in their industry. Andrew Tropeano, the host of NewsWatch and business expert, ... are designed to strengthen the skin’s defense system from the inside out. , According ...
(Date:7/29/2015)... ... 29, 2015 , ... HealthPostures ( https://healthpostures.com ), a sit ... an ergonomics specialty firm. Purpose of the partnership is to help strengthen and ... improve worker mobility, functionality and fitness levels. , Executives at HealthPostures and ...
Breaking Medicine News(10 mins):Health News:New Medical Director Readies To Take Reins at Monarch Landing 2Health News:New Medical Director Readies To Take Reins at Monarch Landing 3Health News:Little City Receives $500,000 Matching Grant from The Coleman Foundation 2Health News:Little City Receives $500,000 Matching Grant from The Coleman Foundation 3Health News:Zofran Lawsuit News: Zofran Lawsuits Stayed, Awaiting MDL Decision 2Health News:Zofran Lawsuit News: Zofran Lawsuits Stayed, Awaiting MDL Decision 3Health News:Zofran Lawsuit News: Zofran Lawsuits Stayed, Awaiting MDL Decision 4Health News:Strengthen the Skin’s Defense System from the Inside Out with mybody 2Health News:HealthPostures and 247Ergo Partnership Strengthens America's Wellness 2Health News:HealthPostures and 247Ergo Partnership Strengthens America's Wellness 3
... ... Ovu-Trac®, an Ovulation Predictor Kit now available in the United States ... accuracy. This fertility predictor has been used successfully by tens of ... Administration requirements for legal sale in the United States. The kit allows ...
... Bariatric ... (7th) consecutive year and will be located in Booth #1011. , ... Irvine, CA (PRWEB) June 18, 2009 -- Bariatric ... seventh (7th) consecutive year and will be located in Booth #1011. "Bariatric Advantage is ...
... different approach to choosing the best treatment options for early ... experts in a report from the 11th St Gallen conference. ... Annals of Oncology [1] today (Thursday 18 June), ... emerged from the conference of more than 4,800 participants from ...
... to Mayo Clinic for patients from around the region, nation and ... are available on the Mayo Clinic News Blog: http://newsblog.mayoclinic.org/2009/06/16/mayo-clinic-gateway/ ... Mayo Clinic announced today that it has signed a letter of ... of Mall of America (R). Over the next 12 months, ...
... Doctors at Allure Medical Spa Are First in Michigan to Use ... --The rumor has been out for a while that the new ... ever competition in the fight against wrinkles. While the jury ... in Shelby Township, is the first medical office in Michigan to ...
... for delinquent kids showed surprise benefit , WEDNESDAY, June ... history of juvenile delinquency in specialized foster-care programs had ... researchers found. , Researchers directed 166 girls aged 13 ... receive treatment for criminal behavior to either specialized foster ...
Cached Medicine News:Health News:Ovu-Trac(R) Home Test Kit From OvumOptics Predicts Ovulation with 96.2% Accuracy 2Health News:Ovu-Trac(R) Home Test Kit From OvumOptics Predicts Ovulation with 96.2% Accuracy 3Health News:Ovu-Trac(R) Home Test Kit From OvumOptics Predicts Ovulation with 96.2% Accuracy 4Health News:Bariatric Advantage Will Be in Attendance at the 26th Annual American Society of Metabolic and Bariatric Surgery in Dallas, Texas 2Health News:St. Gallen consensus 2009: A radically different approach to treating early breast cancer 2Health News:St. Gallen consensus 2009: A radically different approach to treating early breast cancer 3Health News:Mayo Clinic Plans Facility at Mall of America 2Health News:Mayo Clinic Plans Facility at Mall of America 3Health News:Does Botox(R) Finally Have Competition? 2Health News:Close Monitoring May Help Troubled Teen Girls Avoid Pregnancy 2
(Date:7/28/2015)... LOUIS, July 28, 2015  Express Scripts Holding Company ... income attributable to Express Scripts stockholders of $600.1 million, ... share, as detailed in Table 4, were $1.44 for ... is clear many companies across healthcare are validating the ... and Chief Executive Officer. "But, what matters most is ...
(Date:7/28/2015)... , July 28, 2015 /PRNewswire-USNewswire/ -- ... abuse and doctor shopping after a 2012 law required ... and addictive medications is yet more evidence that Californians ... Since Kentucky,s prescription ... "doctor shopping" declined by 52 percent; opioid prescriptions to ...
(Date:7/28/2015)... 2015 A German Diabetes Center clinical study ... probiotic enriches human gut microbiota and modifies gut ... study involved daily administration of Nutraceutix,s L. reuteri ... patented BIO- tract ® delivery technology that ... their way to the intestinal tract. The ...
Breaking Medicine Technology:Express Scripts Announces 2nd Quarter Results; Increases 2015 Guidance Range 2Express Scripts Announces 2nd Quarter Results; Increases 2015 Guidance Range 3Express Scripts Announces 2nd Quarter Results; Increases 2015 Guidance Range 4Express Scripts Announces 2nd Quarter Results; Increases 2015 Guidance Range 5Express Scripts Announces 2nd Quarter Results; Increases 2015 Guidance Range 6Express Scripts Announces 2nd Quarter Results; Increases 2015 Guidance Range 7Express Scripts Announces 2nd Quarter Results; Increases 2015 Guidance Range 8Express Scripts Announces 2nd Quarter Results; Increases 2015 Guidance Range 9Express Scripts Announces 2nd Quarter Results; Increases 2015 Guidance Range 10Express Scripts Announces 2nd Quarter Results; Increases 2015 Guidance Range 11Express Scripts Announces 2nd Quarter Results; Increases 2015 Guidance Range 12Express Scripts Announces 2nd Quarter Results; Increases 2015 Guidance Range 13Express Scripts Announces 2nd Quarter Results; Increases 2015 Guidance Range 14Express Scripts Announces 2nd Quarter Results; Increases 2015 Guidance Range 15Express Scripts Announces 2nd Quarter Results; Increases 2015 Guidance Range 16Express Scripts Announces 2nd Quarter Results; Increases 2015 Guidance Range 17Express Scripts Announces 2nd Quarter Results; Increases 2015 Guidance Range 18Express Scripts Announces 2nd Quarter Results; Increases 2015 Guidance Range 19Express Scripts Announces 2nd Quarter Results; Increases 2015 Guidance Range 20Express Scripts Announces 2nd Quarter Results; Increases 2015 Guidance Range 21Express Scripts Announces 2nd Quarter Results; Increases 2015 Guidance Range 22Express Scripts Announces 2nd Quarter Results; Increases 2015 Guidance Range 23Express Scripts Announces 2nd Quarter Results; Increases 2015 Guidance Range 24Express Scripts Announces 2nd Quarter Results; Increases 2015 Guidance Range 25Study Shows Requiring Prescription Drug Database Use Before Prescribing Powerful, Addictive Medications Critical In Ending Growing Epidemic, says Consumer Watchdog 2Nutraceutix's L. reuteri Probiotic Clinically Proven to Modulate Gut Insulin Metabolism 2
Anterior Chamber Needle, 23 g. Angled. 7 mm angled tip. Overall length 23 mm. 5/box....
Hydrodissection / Aspiration Cannula, 25 g. Angled with right hook. 10 mm angled shaft with 2.5 mm right hook tip. Overall length 20 mm. 5/box....
Silicone Capsule Polisher, 27 g. Silicon tip to provide squeegee effect. Overall length 22 mm. 5/box....
Cystotome Curved, Twisted Tip, 27 g. Twisted tip places cutting edge in line with cannula shaft for vertical cuts during capsulotomies. Overall length 14 mm. 5/box....
Medicine Products: